US4086347A
Expired / Lapsed
US
⏱️ 0.0 years remaining
9-[3-(4-Phenoxymethylpiperidino)-propyl]-adenines
Assignee: Roche Diagnostics GmbH
•
Filing: 1976-11-02
•
Granted: 1978-04-25
•
Expires: 1996-11-02
Abstract
Abstract 9-[3-(4-Phenoxymethylpiperidino)-propyl]-adenines of the formula <IMAGE> wherein R1 is a hydrogen atom or a lower alkyl radical, R2 is a hydrogen atom, a ower alkyl radical optionally substituted by hydroxyl, or a cycloalkyl radical, or R1 and R2 together with the nitrogen atom to which they are attached form a heterocyclic ring, and R3 is a hydrogen atom, a halogen atom, a lower alkyl radical or a lower alkoxy radical, IN THE FORM OF THE FREE BASE OR A SALT THEREOF, EXHIBIT ANTI-ALLERGIC, ANTI-INFLAMMATORY, ANTI-OEDEMATOUS AND ANTI-HYPERTENSIVE ACTIVITY.
Inventors
- 👤 Walter-Gunar Friebe
- 👤 Max Thiel
- 👤 Kurt Stach, deceased
- 👤 administrator by Werner Plattner
- 👤 Otto-Henning Wilhelms
- 👤 Erika VON Mullendorff
- 👤 Gisbert Sponer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 04:27
CPC Classifications
C; C07; C07D; C07D473/00; C07D473/26; C07D473/32; C07D473/34; A; A61; A61P; A61P29/00; A61P3/00; A61P37/00; A61P37/08; A61P9/00; A61P9/12
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
100 words
A 9-[3-(4-phenoxymethylpiperidino)-propyl]-adenine of the formula ##STR7## wherein R 1 is hydrogen or alkyl of up to 6 carbon atoms, R 2 is hydrogen, alkyl of up to 6 carbon atoms optionally mono-substituted by hydroxyl, or cycloalkyl of up to 6 carbon atoms, or R 1 and R 2 together with the nitrogen atom to which they are attached constitute tetramethyleneimino, pentamethyleneimino or hexamethyleneimino, and R 3 is hydrogen, halogen alkyl of up to 6 carbon atoms or alkoxy of up to 4 carbon atoms, in the form of the free base or a salt thereof with a pharmacologically compatible acid.
Claim 2
Dependent Claim
100 words
A 9-[3-(4-phenoxymethylpiperidino)-propyl]-adenine of the formula ##STR7## wherein R 1 is hydrogen or alkyl of up to 6 carbon atoms, R 2 is hydrogen, alkyl of up to 6 carbon atoms optionally mono-substituted by hydroxyl, or cycloalkyl of up to 6 carbon atoms, or R 1 and R 2 together with the nitrogen atom to which they are attached constitute tetramethyleneimino, pentamethyleneimino or hexamethyleneimino, and R 3 is hydrogen, halogen alkyl of up to 6 carbon atoms or alkoxy of up to 4 carbon atoms, in the form of the free base or a salt thereof with a pharmacologically compatible acid.
Claim 3
Dependent Claim
17 words
An adenine according to claim 1, in the form of a salt with a pharmacologically compatible acid.
Claim 4
Dependent Claim
15 words
An adenine according to claim 1, wherein such compound is 9-[3-(4-phenoxymethylpiperidino)-propyl]-adenine of the formula ##STR8##
Claim 5
Dependent Claim
15 words
An adenine according to claim 1, wherein such compound is 9-{3-[4-chlorophenoxymethyl)-piperidino]-propyl}-adenine of the formula ##STR9##
Claim 6
Dependent Claim
15 words
An adenine according to claim 1, wherein such compound is 9-{3-[4-(4-fluorophenoxymethyl)-piperidino]-propyl}-adenine of the formula ##STR10##
Claim 7
Dependent Claim
17 words
An adenine according to claim 1, wherein such compound is N 6 -methyl-9-[3-(4-phenoxymethylpiperidino)-propyl]-adenine of the formula ##STR11##
Claim 8
Dependent Claim
17 words
An adenine according to claim 1, wherein such compound is N 6 -methyl-9-{3-[4-(4-fluorophenoxymethyl)-piperidino]-propyl}-adenine of the formula ##STR12##
Claim 9
Dependent Claim
25 words
A composition comprising an anti-allergic, anti-inflammatory, anti-oedematous and anti-hypertensive effective amount of an adenine according to claim 1, in admixture with a pharmacologically compatible diluent.
Claim 10
Dependent Claim
27 words
A method of diminishing an allergic condition in a patient which comprises administering to such patient an anti-allergically effective amount of a compound according to claim 1.
Claim 11
Dependent Claim
19 words
The method of claim 9 wherein such compound is 9-[3-(4-phenoxymethylpiperidino)-propyl]-adenine, 9-{3-[4-(2-chlorophenoxymethyl)-piperidino]-propyl}-adenine, 9-{3-[4-(4-fluorophenoxymethyl)-piperidino]-propyl}-adenine, N 6 -methyl-9-[3-(4-phenoxymethylpiperidino)-propyl]-adenine or N 6 -methyl-9-{3-[4-(4-fluorophenoxymethyl)-piperidino]-propyl}-adenine.
Claim 12
Dependent Claim
27 words
A method of diminishing an inflammatory condition in a patient which comprises administering to such patient an anti-inflammatory effective amount of a compound according to claim 1.
Claim 13
Dependent Claim
27 words
A method of diminishing an oedematous condition in a patient which comprises administering to such patient an anti-oedematally effective amount of a compound according to claim 1.
Claim 14
Dependent Claim
27 words
A method of diminishing a hypertensive condition in a patient which comprises administering to such patient an anti-hypertensive effective amount of a compound according to claim 1.
References Cited (Backward Citations)
US3917596A
Cited
US3996361A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-04-24 | 1981-10-24 | 1982-04-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-04-24 | 1985-10-24 | 1986-04-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-04-24 | 1989-10-24 | 1990-04-25 | $7700.00 | Window Closed / Lapsed |